A novel 5-fluorouracil prodrug using hydroxyethyl starch as a macromolecular carrier for sustained release

Carbohydrate Polymers

Volumn 87, Issue 4, 2012, Pages 2642-2647

  Luo, Qing ^a   Wang, Puxiu ^a   Miao, Yuqiang ^a   He, Haibing ^a   Tang, Xing ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

5 Fluorouracil 1 acetic acid; Conjugates; Enzymolysis; Hydrolysis; Hydroxyethyl starch; Pharmacokinetics

Indexed keywords

DRUG PRODUCTS; HYDROLYSIS; PHARMACOKINETICS; RATS;

5-FLUOROURACIL-1-ACETIC ACIDS; ANTITUMOR DRUGS; CONJUGATES; DRUG DELIVERY SYSTEM; ENZYMOLYSIS; HYDROXYETHYL STARCHES; INTRAVENOUS INJECTIONS; SUSTAINED RELEASE;

STARCH;

RATTUS;

EID: 84865662482     PISSN: 01448617     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carbpol.2011.11.039     Document Type: Article

References (23)

1. Brockman, R., & Anderson, E. (1963). Biochemistry of cancer (metabolic aspects). Annual Review of Biochemistry, 32(1), 463-512.
2. Dragsten, P. R., Hallaway, P. E., Hanson, G. J., Berger, A. E., Bernard, B., & Hedlund, B. E. (2000). First human studies with a high-molecular- weight iron chelator. Journal of Laboratory and Clinical Medicine, 135(1), 57-65. (Pubitemid 30042154)
3. Hao, A., Deng, Y., Li, T., Suo, X., Cao, Y., Hao, Y., et al. (2006). Degradation kinetics of fluorouracil-acetic-acid-dextran conjugate in aqueous solution. Drug Development and Industrial Pharmacy, 32(6), 757-763. (Pubitemid 44181202)
4. Hashida, M., & Takakura, Y. (1994). Pharmacokinetics in design of polymeric drug delivery systems. Journal of Controlled Release, 31(2), 163-171. (Pubitemid 24268162)
5. Hershenson, H. (1970). Starch plasma expanders and process of preparation. US Patent 3,523,938.
6. Jain, R. K. (1987). Transport of molecules across tumor vasculature. Cancer and Metastasis Reviews, 6(4), 559-593.
7. Jiang, T. Y., Wang, S. L., Sun, C. S., Chang, D., Yu, F. B., & Mo, F. K. (2008). The investigation on a conjugate of 5-fluorouracil-1-acetic acid and galactosylated poly (aspartamide): Synthesis, stability and liver targeting. Journal of Drug Delivery Science and Technology, 18(4), 225-230.
8. Larsen, C. (1989). Macromolecular prodrugs XII. Kinetics of release of naproxen from various polysaccharide ester prodrugs in neutral and alkaline solution. International Journal of Pharmaceutics, 51(3), 233-240. (Pubitemid 19117171)
9. Lockridge, O., & Quinn, D. M. (2010). Esterases. In A. M. Charlene (Ed.), Comprehensive toxicology (pp. 243-273). Oxford: Elsevier.
10. Macdonald, J. S. (1999). Toxicity of 5-fluorouracil. Oncology (Williston Park, NY), 13(7 (Suppl. 3)), 33-34. (Pubitemid 29379208)
11. Ouchi, T., Banba, T., Fujimoto, M., & Hamamoto, S. (1989). Synthesis and antitumor activity of chitosan carrying 5-fluorouracils. Die Makromolekulare Chemie, 190(8), 1817-1825.
12. Ouchi, T., Hagihara, Y., Takahashi, K., Takano, Y., & Igarashi, I. (1992). Synthesis and antitumor activity of poly(ethylen glycol)s linked to 5-fluorouracil via a urethane or urea bond. Drug Design and Discovery, 9(1), 93-105.
13. Petrak, K., & Goddard, P. (1989). Transport of macromolecules across the capillary walls. Advanced Drug Delivery Reviews, 3(2), 191-214. (Pubitemid 19146030)
14. Sang Mok, C., Eun Jeong, Y., So Hee, K., Myung Gull, L., Heejoo, L., Man Ki, P., et al. (1991). Pharmacokinetics of 5-fluorouracil after intravenous infusion of 5-fluorouracil-acetic acid-human serum albumin conjugates to rabbits. International Journal of Pharmaceutics, 68(1-3), 61-68.
15. Sezaki, H., & Hashida, M. (1984). Macromolecule-drug conjugates in targeted cancer chemotherapy. Critical Reviews in Therapeutic Drug Carrier Systems, 1(1), 1-38. (Pubitemid 15062288)
16. Sezaki, H., Takakura, Y., & Hashida, M. (1989). Soluble macromolecular carriers for the delivery of antitumour drugs. Advanced Drug Delivery Reviews, 3(2), 247-266. (Pubitemid 19146033)
17. Tada, M. (1975). Antineoplastic agents. The preparation of 5-fluorouracil-1-acetic acid derivatives. Bulletin of the Chemical Society of Japan, 48(11), 3427-3428.
18. Takakura, Y., & Hashida, M. (1995). Macromolecular drug carrier systems in cancer chemotherapy: Macromolecular prodrugs. Critical Reviews in Oncology/ Hematology, 18(3), 207-231.
19. Udo, K., Hokonohara, K., Motoyama, K., Arima, H., Hirayama, F., & Uekama, K. (2010). 5-Fluorouracil acetic acid/[beta]-cyclodextrin conjugates: Drug release behavior in enzymatic and rat cecal media. International Journal of Pharmaceutics, 388(1-2), 95-100.
20. Waitzinger, J., Bepperling, F., Pabst, G., & Opitz, J. (2003). Hydroxyethyl starch (HES) 130/0.4, a new HES specification: Pharmacokinetics and safety after multiple infusions of 10 solution in healthy volunteers. Drugs in R & D, 4(3), 149-157. (Pubitemid 36849662)
21. Wang, Q., Liu, X., Liu, L., Feng, J., Li, Y., Guo, Z., et al. (2007). Synthesis and evaluation of the 5-fluorouracil-pectin conjugate targeted at the colon. Medicinal Chemistry Research, 16(7), 370-379.
22. Westphal, M., James, M. F. M., Kozek-Langenecker, S., Stocker, R., Guidet, B., & Van Aken, H. (2009). Hydroxyethyl starches: Different products-different effects. Anesthesiology, 111(1), 187-202.
23. Yang, Z., Wang, L., Yang, X., Wang, D., & Li, Y. (2000). Pharmacological study on antitumor activity of 5-fluorouracil-1-acetic acid and its rare earth complexes. Journal of Rare Earths, 18(2), 140-143. (Pubitemid 34092258)